Trial reportClinical journal of the American Society of Nephrology : CJASN2014
Efficacy of levofloxacin in the treatment of BK viremia: a multicenter, double-blinded, randomized, placebo-controlled trial.
Trial report in Clinical journal of the American Society of Nephrology : CJASN, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 2 syntheses or guidelines pooled it, 94 citations in OpenAlex.
- Interventions for BK virus infection in kidney transplant recipients.The Cochrane database of systematic reviews · 2024Pooled it
- Fluoroquinolone prophylaxis in preventing BK polyomavirus infection after renal transplant: A systematic review and meta-analysis.The Kaohsiung journal of medical sciences · 2016Pooled it
- A randomized, placebo-controlled, dose-escalation phase I/II multicenter trial of low-dose cidofovir for BK polyomavirus nephropathy.Transplant infectious disease : an official journal of the Transplantation Society · 2024Trial
- BK Nephropathy in the Modern Era: What Have We Learned?Kidney360 · 2025Review
- Review
- Risk factors and outcome of BK polyomavirus infection in pediatric kidney transplantation.Pediatric nephrology (Berlin, Germany) · 2024Article
- BK Polyomavirus Infection in Kidney Transplantation: A Comprehensive Review of Current Challenges and Future Directions.International journal of molecular sciences · 2024Review
- BK viral infection: A review of management and treatment.World journal of transplantation · 2023Review
- Viral Infection and Antiviral Treatments in Ocular Pathologies.Microorganisms · 2022Review
- Review
- Long-Term Infectious Complications of Kidney Transplantation.Clinical journal of the American Society of Nephrology : CJASN · 2022Review
- Intracellular Low Iron Exerts Anti-BK Polyomavirus Effect by Inhibiting the Protein Synthesis of Exogenous Genes.Microbiology spectrum · 2021Article
- BK virus infection and outcome following kidney transplantation in childhood.Scientific reports · 2021Article
- The Role of HLA and KIR Immunogenetics in BK Virus Infection after Kidney Transplantation.Viruses · 2020Review
- Pathogenicity of BK virus on the urinary system.Central European journal of urology · 2020Review
- Symptomatic BK virus cystitis in non-renal transplant recipients.Journal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada · 2019Article
- Non-immunological complications following kidney transplantation.F1000Research · 2019Review
- Common viral infections in kidney transplant recipients.Kidney research and clinical practice · 2018Review
- BK Polyomavirus: Clinical Aspects, Immune Regulation, and Emerging Therapies.Clinical microbiology reviews · 2017Review
- Outcomes of renal transplant recipients with BK virus infection and BK virus surveillance in the Auckland region from 2006 to 2012.World journal of nephrology · 2016Article
Corrections and comments
- Commented on by
Authors and funding
13 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesBK virus reactivation in kidney transplant recipients can lead to progressive allograft injury. Reduction of immunosuppression remains the cornerstone of treatment for active BK infection. Fluoroquinolone antibiotics are known to have in vitro antiviral properties, but the evidence for their use in patients with BK viremia is inconclusive. The objective of the study was to determine the efficacy of levofloxacin in the treatment of BK viremia. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Enrollment in this prospective, multicenter, double-blinded, placebo-controlled trial occurred from July 2009 to March 2012. Thirty-nine kidney transplant recipients with BK viremia were randomly assigned to receive levofloxacin, 500 mg daily, or placebo for 30 days. Immunosuppression in all patients was adjusted on the basis of standard clinical practices at each institution. Plasma BK viral load and serum creatinine were measured monthly for 3 months and at 6 months.
resultsAt the 3-month follow-up, the percentage reductions in BK viral load were 70.3% and 69.1% in the levofloxacin group and the placebo group, respectively (P=0.93). The percentage reductions in BK viral load were also equivalent at 1 month (58% versus and 67.1%; P=0.47) and 6 months (82.1% versus 90.5%; P=0.38). Linear regression analysis of serum creatinine versus time showed no difference in allograft function between the two study groups during the follow-up period.
conclusionsA 30-day course of levofloxacin does not significantly improve BK viral load reduction or allograft function when used in addition to overall reduction of immunosuppression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.